Tissue Factor Antibody Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, thrombosis, and inflammation related to tissue factor (TF) are limited due to TF's role in promoting tumor growth, metastasis, and coagulation, making it challenging to develop effective therapeutic strategies.
Innovation Solution
Development of a specific antibody targeting human TF, which inhibits tumor growth, metastasis, and coagulation by binding to TF with high affinity, thereby blocking the TF-PAR2 signal pathway and reducing the production of activated coagulation factor X.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TF is targeted for inhibition to treat cancer, then tumor growth and metastasis are suppressed, but coagulation function may be affected
Solution Approach 1:
The antibody exhibits selective binding to pathological TF states (TF-FVIIa complex or activated TF conformation) rather than all TF forms, achieving localized inhibition of pro-coagulative and pro-metastatic pathways while preserving normal physiological coagulation function through differential recognition of TF molecular states
Solution Approach 2:
Instead of inhibiting TF's normal coagulation function directly, the antibody targets the abnormal activated state of TF (TF-FVIIa complex) that occurs in cancer and thrombosis, inverting the approach from blocking physiological function to neutralizing pathological activation
2Reliability
If broad-spectrum anticoagulants are used to treat thrombosis, then coagulation is inhibited, but tumor growth may be promoted
Solution Approach 1:
The antibody serves as a selective intermediary that specifically blocks the TF-FVIIa complex formation and downstream signaling pathways, providing targeted anticoagulation effect without the broad-spectrum anti-coagulant effects that promote tumor growth, thereby mediating therapeutic separation between thrombosis treatment and tumor protection
3Reliability
If TF inhibitors are developed to block PAR2 signaling, then inflammatory response is reduced, but coagulation control becomes difficult
Solution Approach 1:
The antibody specifically segments and blocks the TF-PAR2 signaling pathway while leaving other coagulation pathways (intrinsic pathway, thrombin generation) intact, achieving selective anti-inflammatory effect through PAR2 inhibition without compromising overall coagulation control mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody effectively inhibits tumor growth, metastasis, and coagulation, offering a potential therapeutic approach for TF-related diseases such as cancer, thrombosis, and inflammation with minimal toxic side effects.
Implementation Method 1
a specific antibody targeting human TF, which inhibits tumor growth, metastasis, and coagulation by binding to TF with high affinity
Implementation Method 2
TF will be exposed to the blood stream, and initiates extrinsic coagulation reaction by binding to and activating factor VII
Data Source
AI summary
The present invention provides a tissue factor (TF) monoclonal antibody and a preparation method therefor. The monoclonal antibody provided by the present invention can specifically bind with a TF antigen, has high affinity and low immunogenicity, and has the activity of resisting tumors and the like.